Search results for: 'learning ad developments'

Microbiome research is on the rise following technological advancements and significant cost reductions in microbiome analysis. Research has unlocked the potential of microbiome in medical use cases, yielding tremendous insights on its nature, interactions, and impact within a host and in an external environment. Advanced studies on the role of mic...

The global pharmaceutical research and development (R&D) pipeline accounts for more than 21,000 molecules, as of April 2023, indicating a 5.8% hike over 2022, with more than 6,100 molecules in active development. In general, however, the pharma/biopharma industry has stagnated with respect to R&D activity. Overall R&D expenditure totals about $276....

By 2023, biologics constituted 44% of the therapeutic pipeline, with antibodies and recombinant proteins as leading categories. Nevertheless, advancements in these fields decelerated, with most of the expansion happening in heterologous cell treatments, synthetic nucleic acids, and viruses. The global biologics pipeline will shift toward more compl...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides actionable insights across new developments in prebiotics, immunology, oncology, cell and gene therapies, antibody therapies, and precision medicine approaches. The TOE also encompasses technology advances across the use of AI and ML in drug discovery a...

The global small‑molecule CDMO industry is undergoing a structural transformation driven by increasing molecular complexity, patent expiries, cost pressures, and the strategic need to secure resilient pharmaceutical supply chains. Demand is shifting beyond high‑volume commodity generics toward specialized development and manufacturing capabilities ...

The SynBio field has evolved well over the past two decades, with significant technology disruptions leading to new opportunities and remarkable growth potential. Advances in SynBio technologies have transformed drug discovery and therapeutics development, accelerating the identification of novel drug targets and high-throughput compound screening ...

Digitalization of the entire value chain will drive next-generation biomanufacturing. The industry is all set to move away from the traditional pen-and-paper-based process to a more advanced, digitized, track-and-trace process that is aligned toward Industry 4.0. Digital tools applied across processes, monitoring, analytics, and operations have acc...

The conventional drug discovery and diagnostics technologies are unable to cope up with the current disease management practices. To this end, researchers have explored possibilities beyond life sciences. Specifically, they have figured out that the use of engineering principles to biological systems can revolutionize the drug discovery and diagnos...

17 Jun 2021  |  North America  |  Market Research

Global Biologics Contract Development and Manufacturing Organizations Growth Opportunities

Asset Co-Development with Clinical-stage Biopharmaceutical Companies and Disruptive Technologies Present Future Growth Potential

Infographics

×

This study presents Frost & Sullivans overall market and segment-wise revenue forecasts of the global biologics contract development and manufacturing organizations (bio-CDMO) market. It also highlights key growth opportunities for bio-CDMO market participants based on the main evolution in their business models and strategic approaches, as well as...